A number of pharmaceutical companies in the second quarter of the decline, not as expected!

"Pharmaceutical Network Industry Dynamics" Recently, a number of multinational pharmaceutical companies have released a series of second-quarter financial results.
, revenue and net profit increased or decreased, but overall, they fell short of expectations. On July 28,
, Anjin reported second-quarter 2020 revenue of $6.2 billion, up 6% year-on-year, with product sales of $5.9 billion, up 6% and profit of $1.8 billion, down 17%.
, Aminhas reiterated its full-year revenue outlook, forecasting between $25-25.6 billion and raising its earnings per share forecast.
same day, Pfizer also reported second-quarter 2020 earnings of $11.801 billion, down 9% year-on-year.
, however, Pfizer's innovative biopharmaceutical business, revenue rose 6 per cent year-on-year to $9.795bn, excluding up-taking arm Upjohn.
currently in the process of merging with Mylan, upjohn and Mylan are expected to complete in the second half of the year.
unlike the previous two, Vas Narasimhan, chief executive of Novartis Pharmaceuticals, a Swiss pharmaceutical company, said on July 21st that the "very damaging environment" created a "very damaging environment" that darkened the company's 2020 revenue outlook, with sales and profits both falling in the second quarter.
second quarter, Novartis's net profit fell 4 percent to $1.9 billion, compared with $2.1 billion a year earlier, and sales fell 1 percent to $13.35 billion.
, some analysts said Novartis' sales fell 7 per cent in the second quarter than the bank expected.
or results, Novartis was down 1.49 per cent in pre-market trading as of July 21.
in fact, under the impact of the epidemic, the global pharmaceutical industry is deepening the degree of division, performance gains have also appeared to fluctuate, which from many pharmaceutical companies' half-yearly report card can be seen.
only in China, A-share 110 listed pharmaceutical companies on the performance forecast is seriously polarized, the performance of the difference is obvious.
, about 86 enterprises can achieve pre-growth, 31 enterprises will increase by more than 100%, 14 enterprises will grow between 50% and 100%.
increased significantly in British medicine, by 2864.1%.
but the decline was significant, but the international medical system reached 7164.68 percent.
based on this, the second quarter of the drug company's performance changes, but also most people expected.
in fact, for the vast majority of domestic pharmaceutical companies, the current situation is worse than the impact of the outbreak of multinational enterprises.
in 2019 to introduce a series of consistency evaluation, volume procurement, auxiliary drug regulation and a series of policies, the impact of domestic pharmaceutical companies have entered a cruel knockout, is constantly a pharmaceutical companies "down."
Cornbey, the leading chinese medicine leader in China, sold its own shares in two subsidiaries at the end of last year and "sold" themthis year. On April 2,
, Cornbey Group signed an agreement to transfer 20% of Cornbey's shares to Zhejiang Province's Chinese Medicine Health Industry Group.
If the implementation of this share transfer is completed, Connbei Group And its co-actions, Hu Jiqiang, Zhejiang Bokang Pharmaceutical Investment will hold a total of 13.33%, the second largest shareholder.
the actual controller of the company, will be changed from Hu Jiqiang to the State-owned Assets Supervision and Administration Commission of Zhejiang Province.
in general, outbreaks are prompting many sub-tracks to accelerate into the stage of change and integration, either actively or passively.
as a result, the industry expects mergers and acquisitions to be the main theme of the pharmaceutical industry in 2020.
especially for the industry giants, the strength of which may usher in unprecedented opportunities for enterprise building and industry consolidation.
.